Carmen Bozic, Chief Medical Officer and Executive Vice President, on June 15, 2026, sold 4,062 shares in Vertex Pharmaceuticals (VRTX) for $1,827,900. Following the Form 4 filing with the SEC, Bozic has control over a total of 16,953 common shares of the company, with 16,953 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/875320/000087532026000235/xslF345X05/wk-form4_1781727153.xml
Hannah Valantine, Director, on June 12, 2026, sold 12,103 shares in Caredx (CDNA) for $279,728. Following the Form 4 filing with the SEC, Valantine has control over a total of 36,686 common shares of the company, with 36,686 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1217234/000185560826000003/xslF345X05/form4-06162026_090624.xml
Andrew D Dickinson, Chief Financial Officer, on June 15, 2026, sold 3,000 shares in Gilead Sciences (GILD) for $376,200. Following the Form 4 filing with the SEC, Dickinson has control over a total of 171,646 common shares of the company, with 171,646 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/882095/000131020426000020/xslF345X05/wk-form4_1781646803.xml
Suzanne L Helen, Possible Member of Group, on June 12, 2026, sold 5,742 shares in Mohawk Industries (MHK) for $637,951. Following the Form 4 filing with the SEC, Helen has control over a total of 177,378 common shares of the company, with 177,378 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/851968/000127137326000007/xslF345X05/primary_doc.xml